Investor Relations

Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. Connect with us on X, LinkedIn and Facebook.

Latest Financial Results

Q2 2025

Quarter Ended Jun 30, 2025
Earnings Release
10-Q XBRL Zip

Latest News

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

View Press Release View All News

Upcoming Events

European Society for Medical Oncology (ESMO) Congress 2025

View Event Add to Calendar View All Events

IR Contacts

Company

Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
T: 617.963.0100
info@corbuspharma.com

Investor Relations

Corbus Pharmaceuticals
Sean Moran
Chief Financial Officer
ir@corbuspharma.com

LifeSci Advisors, LLC
Daniel Ferry
Managing Director
daniel@lifesciadvisors.com

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004
T: 800.509.5586
cstmail@continentalstock.com
https://www.continentalstock.com

Connect With Us